Although AR-targeted drugs have shown significant efficacy in PCa treatment, intrinsic and acquired resistance to androgen receptor pathway inhibitor (ARPI) is a major problem in this treatment, which is closely associated with poor prognosis in patients with PCa [7,8]. The gene discussed is AR; the disease is posterior cortical atrophy.